20 January 2023 in Clinical Otolaryngology
19 February 2020 in Ear, Nose & Throat Journal
Sudden sensorineural hearing loss is a common otologic disease in clinic. Systemic and intratympanic steroid treatment have been proved to be effective, but the regimens vary from center to center. The purpose of the study is to analyze the effects of the combined application of intravenous dexamethasone and intratympanic methylprednisolone injection in different time strategies for the treatment of unilateral sudden sensorineural hearing loss. A retrospective chart review was performed for the period from March 2016 to June 2018 at our Department of Otorhinolaryngology—Head and Neck Surgery. A total number of 61 patients who met the academy criteria for unilateral sudden hearing loss were included and grouped based on the time to introduce intratympanic methylprednisolone. All the patients received intravenous dexamethasone 10 mg once daily for 5 days, followed 5 mg once daily for the next 7 days. Intratympanic methylprednisolone (40 mg) was injected every other day 4 times into all patients. This regimen was commenced on day 1 in group 1 and on day 6 in group 2. The pre and posttreatment pure-tone audiograms were analyzed. Sixty-one patients met our inclusion criteria. No significant differences were observed between patients’ demographics or pretreatment hearing thresholds. In the 3 months posttreatment pure-tone audiogram assessment, the mean hearing threshold improvement were similar between groups with no frequency specificity. The curative rate in both groups were similar and satisfying. Two patients with diabetes mellitus had persistent small perforations. Some patients had other transient discomfort that disappeared before discharge. The different timing of initiation of intratympanic methylprednisolone injection does not significantly affect the outcome of the treatment for sudden sensorineural hearing loss. Thus, we suggest that intratympanic steroid injection should not be applied as a first-line method except for patients who do not respond early to systemic steroid therapy.
2 November 2026 in World Journal of Otorhinolaryngology - Head and Neck Surgery
Objective: The aim of this study was to develop effective treatments for episodic laryngeal breathing disorders (ELBD), a series of diverse obstructive respiratory disorders with an unknown pathogenesis. The diseases include paradoxical vocal fold motion/movement disorder (PVFMD), vocal cord dysfunction (VCD), irritable larynx syndrome (ILS), exercise‐induced laryngeal obstruction, and laryngospasm. Methods: Five patients with ELBD were involved in this study (60–81 years, average of 70 years), including three men and two women, who visited the otolaryngology outpatient department suffering from dyspnea several times. Bilateral vocal fold paralysis and asthma were excluded. An injection of initial botulinum toxin into the vocal cords was treated for each patient. If recurrence were to take place within 3 months after injection, a vocal cord process resection would be performed. The visual scale of perception was used for assessing preoperative and postoperative dyspnea. Results: All patients experienced symptoms of recurring dyspnea for a duration of 1–120 months. The average follow‐up duration was 14 months (6–24 months) after treatment. Dyspnea was relieved in two patients after the Botox injection alone. Three patients found relief after unilateral vocal cord process resection. All patients showed a significant reduction in postoperative dyspnea scale in VAS score. Conclusion: This study preliminarily explores the efficacy of combined Botox injection and partial arytenoidectomy as a therapeutic option for ELBD.